"99毫居里！"日前，在济南中科核技术研究院里，伴随着一阵欢呼，该院杨文江副研究员团队得到了活度百毫居里量级、核纯度大于99%、放射化学纯度 大于99%的放射性核素钪-44，在我国首次实现了钪-44量产。此举缩小了与国外的差距，为肿瘤诊疗提供了一种分辨率更高、更方便制药的显像剂。 13日，记者在济南中科核技术研究院看到，隔着4米厚的墙，实验人员用回旋加速器"轰击"天然硝酸钙靶。"质子把钙-44原子核的一个中子'撞'出来，就得 到钪-44。"该院副研究员王一正告诉记者，钪-44生产工艺复杂，此前国内只能做到实验室量级。而国外10年前便开始研发，已实现量产，进行了药物研 发与临床试验。 孙晓蓉介绍，当前临床最常用的放射性同位素是氟-18，将其标记到脱氧葡萄糖上，就得到了FDG（氟代脱氧葡萄糖）示踪剂，能敏锐地发现多种糖代谢 旺盛的肿瘤。但氟-18半衰期仅110分钟，必须凌晨生产、清晨配送，像"鲜牛奶"一样过期作废；而且正常脑组织本身就在大量"吃糖"，脑肿瘤的信号常被 淹没，很难分辨；对于一些糖代谢不旺盛的肿瘤也常漏诊。 她说，另一种常用的放射性同位素镓-68是一种金属元素，更易于与识别肿瘤特异性靶点的药物结合，在 ...

经济观察网市场监管总局批准建立我国首套β辐射组织吸收剂量国家基准装置，该装置由中国计量科学 研究院研制，旨在提升放射医疗、核能安全等领域的测量标准精度。作为核医学相关企业，中国同辐 (01763.HK)可能间接受益于行业技术升级，但需关注后续政策落地对业务的实际影响。 近7个交易日(2026年2月5日至11日)，中国同辐股价区间涨幅1.48%，但波动显著：2月5日跌2.23%，2月 6日续跌1.42%，随后2月9日及10日分别反弹3.18%和2.33%，2月11日微跌0.27%至21.88港元。技术面 上，MACD柱状图转负(2月11日为-0.113)，KDJ指标从超卖区域回升至54.19(K线)，显示短期震荡；资 金流向方面，主力净流出持续，2月11日净流出84.89万港元，反映部分资金获利了结。 以上内容基于公开资料整理，不构成投资建议。 股票近期走势 ...

今后，原子高科将持续深耕核医学领域，聚焦重大疾病诊疗需求，加大核素药物研发与技术创新投入， 以更优质的产品与服务助力精准医疗发展，为守护人民健康筑起更坚实的屏障。 中国同辐(01763)公布，近日，原子高科股份有限公司(以下简称：原子高科)利用30MeV质子回旋加速 器，首次实现放射性核素锗-68的国产规模化制备，各项指标均符合欧美商业化产品核素要求，这标志 着我国正式具备自主、稳定的锗-68规模化生产能力，为肿瘤患者精准诊断治疗带来福音。目前，世界 上仅有少数国家攻克了锗-68的规模化制备技术。 锗-68是放射性核素镓-68的母体核素，通过衰变生成镓-68。镓-68标记的放射性药物，在核医学领域可 以用于肿瘤的正电子扫描(PET)诊断显像，能够为肿瘤临床诊断治疗提供重要依据。目前，国外已有多 款镓-68药物获批上市用于癌症的诊断，国内亦有13款镓-68药物进入了临床。随着镓-68药物的获批和大 量使用，锗-68在国内外市场的应用前景广阔。 ...

中国同辐(01763)公布，近日，原子高科股份有限公司(以下简称：原子高科)利用30MeV质子回旋加速 器，首次实现放射性核素锗-68的国产规模化制备，各项指标均符合欧美商业化产品核素要求，这标志 着我国正式具备自主、稳定的锗-68规模化生产能力，为肿瘤患者精准诊断治疗带来福音。目前，世界 上仅有少数国家攻克了锗-68的规模化制备技术。 锗-68是放射性核素镓-68的母体核素，通过衰变生成镓-68。镓-68标记的放射性药物，在核医学领域可 以用于肿瘤的正电子扫描(PET)诊断显像，能够为肿瘤临床诊断治疗提供重要依据。目前，国外已有多 款镓-68药物获批上市用于癌症的诊断，国内亦有13款镓-68药物进入了临床。随着镓-68药物的获批和大 量使用，锗-68在国内外市场的应用前景广阔。 今后，原子高科将持续深耕核医学领域，聚焦重大疾病诊疗需求，加大核素药物研发与技术创新投入， 以更优质的产品与服务助力精准医疗发展，为守护人民健康筑起更坚实的屏障。 ...

格隆汇1月29日丨中国同辐(01763.HK)公告，以下公告的中文原稿由中国同辐股份有限公司旗下一间于 全国中小企业股份转让系统上市的附属公司，原子高科股份有限公司(股份代号：430005)于中国境内发 布。 近日，原子高科股份有限公司(以下简称：原子高科)利用30MeV质子回旋加速器，首次实现放射性核素 锗-68的国产规模化制备，各项指标均符合欧美商业化产品核素要求，这标志着我国正式具备自主、稳 定的锗-68规模化生产能力，为肿瘤患者精准诊断治疗带来福音。目前，世界上仅有少数国家攻克了 锗-68的规模化制备技术。 锗-68是放射性核素镓-68的母体核素，通过衰变生成镓-68。镓-68标记的放射性药物，在核医学领域可 以用于肿瘤的正电子扫描(PET)诊断显像，能够为肿瘤临床诊断治疗提供重要依据。目前，国外已有多 款镓-68药物获批上市用于癌症的诊断，国内亦有13款镓-68药物进入了临床。随着镓-68药物的获批和大 量使用，锗-68在国内外市场的应用前景广阔。 今后，原子高科将持续深耕核医学领域，聚焦重大疾病诊疗需求，加大核素药物研发与技术创新投入， 以更优质的产品与服务助力精准医疗发展，为守护人民健康筑起更坚 ...

Group 1 - The core theme of the recent municipal meetings is "enhancing capability," which encompasses not only growth in scale and speed but also the restructuring of development momentum, industrial structure, and competitive positioning [2] - This year marks the beginning of the "14th Five-Year Plan," and the strategy for "enhancing capability" outlines a clear path for promoting high-quality regional economic development [2] Group 2 - Building a modern industrial system is identified as a primary task across various regions, focusing on strengthening advantageous industries, exploring the potential of traditional manufacturing, and establishing brand recognition for emerging and specialty industries [3] - Yibin has experienced a 60% growth in industrial added value over the past five years, with its power battery industry leading nationally and its photovoltaic industry ranking first in the province [5] - In 2025, despite industry pressures, Yibin's photovoltaic industry is projected to reach a scale of 37 billion yuan, reflecting a year-on-year growth of 28.5% [5] Group 3 - Nanchong is focusing on upgrading traditional manufacturing through quality improvement and strengthening supply chains, with a significant milestone achieved in the production of a new model of commercial vehicles [6] - Nanchong has 219 enterprises in the automotive and parts industry, and it plans to accelerate the construction of a circular economy industrial park to address gaps in mechanical manufacturing [6] Group 4 - Leshan is restructuring its industrial landscape through systematic layout and strengthening industrial chains, aiming to stabilize its advantageous industries while enhancing the support of specialty industries [7] - The city is promoting the development of photovoltaic energy storage and green chemical industries, while also extending the application of nuclear technology in various sectors [7] Group 5 - Luzhou is focused on cultivating competitive specialty industrial clusters, particularly in nuclear medicine, and aims to establish itself as a "nuclear medicine application demonstration city" [8] - Aba Prefecture is prioritizing ecological development and unique resource advantages, with plans to build clean energy bases and a modern seed industry park [8] Group 6 - Innovation and openness are seen as essential for enhancing capability, with discussions on topics like "new integration" and "external openness" being prominent at the municipal meetings [9] - Deyang is integrating technological and industrial innovation, with a focus on the equipment manufacturing sector and the establishment of innovation platforms [10] - Meishan is advancing the integration of new technologies and has established numerous pilot research platforms to facilitate the transformation of scientific achievements [10][11] Group 7 - Meishan has over 560 technology-driven enterprises, emphasizing the role of small and medium-sized tech companies in driving industrial transformation [11] - Both Leshan and Meishan are prioritizing the construction of transportation and logistics hubs as a breakthrough for enhancing openness [11]

Core Viewpoint - The article highlights the achievements of researcher Di Cuixia in the field of heavy ion cancer therapy, emphasizing her innovative contributions and dedication to bridging basic research with clinical needs [1][3]. Group 1: Career Development - Di Cuixia transitioned from a background in plant science to tumor radiotherapy, leveraging her expertise in antibody preparation to make significant strides in cancer research [2][3]. - After returning to China in 2010, she joined the Institute of Modern Physics at the Chinese Academy of Sciences, focusing on heavy ion therapy, which was emerging as a leading technology in cancer treatment [2][3]. Group 2: Research Focus - Di Cuixia's research centers on the mechanisms of heavy ion-induced apoptosis in cancer cells, expanding into areas such as radiation sensitizers, overcoming radiotherapy resistance, and personalized radiotherapy [3][4]. - She has successfully secured multiple research grants, including projects from the National Natural Science Foundation and the Ministry of Science and Technology, to support her innovative research [3][4]. Group 3: Clinical Collaboration - Di Cuixia emphasizes the importance of aligning basic research with clinical needs, actively seeking collaborations with hospitals to obtain clinical samples and data [3][4]. - Her efforts have led to strong partnerships with institutions like Lanzhou University First Hospital and the Cancer Hospital of the Chinese Academy of Medical Sciences, facilitating joint research initiatives [4][5]. Group 4: Innovations and Achievements - Di Cuixia has identified the issue of radiotherapy resistance as a critical challenge and is developing radiation sensitizers to enhance the efficacy of conventional radiotherapy [5]. - Preliminary results indicate that these sensitizers can increase tumor cell sensitivity to conventional radiation, potentially addressing a significant barrier in cancer treatment [5]. Group 5: Outreach and Education - In addition to her research, Di Cuixia is committed to science popularization, engaging with schoolchildren to inspire interest in science through hands-on experiments and relatable explanations [6]. - She believes in the vast potential for growth in the field of nuclear medicine in China, where only 20-30% of cancer patients currently receive radiotherapy compared to 70% in the United States [6].

Group 1 - The event held in Taicang City focused on promoting the standardized application of nuclear technology in disease diagnosis, targeted therapy, and efficacy evaluation, aiming for equitable access to quality nuclear medical resources [1] - The "One County, One Department" strategic research platform for nuclear medicine aims to provide comprehensive solutions for the establishment of nuclear medicine departments in grassroots hospitals, supporting the implementation of the "One County, One Department" strategy [1] - The AI innovation platform for nuclear medicine research wards will enhance clinical research quality and efficiency through AI-enabled solutions for clinical trials, radiomics research, and patient follow-up management [1] Group 2 - The establishment of the Kunrun Shengyan (Suzhou) Technology Co., Ltd. in Shaxi is expected to inject strong momentum into the growth of the local biopharmaceutical industry, leveraging its comprehensive core competencies across software, intelligent hardware, algorithms, and data [2] - Kunrun Shengyan is recognized as a major scientific research achievement transformation enterprise under the national "863" program, filling multiple technological gaps in the industry [2]

Core Viewpoint - China Tongru (01763) announced that the project "Establishment of a Multimodal Nuclear Medicine Molecular Imaging System for Pediatric Neuroblastoma," involving Yuanzi Gaoke Co., Ltd., won the first prize at this year's Beijing Medical Science and Technology Awards [1] Group 1: Project Overview - Neuroblastoma is the most common extracranial solid tumor in children, accounting for approximately 8%-10% of pediatric malignant tumors and leading to about 10%-15% of childhood cancer-related deaths [1] - More than half of the patients are classified as high-risk at initial diagnosis, with a poor prognosis and a five-year survival rate of less than 50% [1] - The project focuses on addressing the challenges posed by neuroblastoma, which is referred to as the "king of childhood cancers," and aims to contribute to public health in China [1] Group 2: Technological Achievements - The project has established a complete independent innovation chain from key equipment and core drugs to clinical applications, creating a "multimodal, low-dose, short-duration" precision diagnosis and treatment system for neuroblastoma [1] - Yuanzi Gaoke has developed the positron-emitting radiopharmaceutical sodium fluoride [18F] injection, completed Phase III clinical trials, and successfully registered it, filling a gap in domestic bone imaging radiopharmaceuticals [2] - The company has also led the development of the iodine [123I] sodium solution radiopharmaceutical group standard and collaborated with the Friendship Hospital to provide a basis for standardized production of domestic radiopharmaceuticals [2] Group 3: Strategic Collaboration - Yuanzi Gaoke and the nuclear medicine department of the Friendship Hospital have established a long-term strategic partnership based on the concept of "industry-university-research-medical collaboration" [2] - The collaboration has resulted in significant advancements in radiopharmaceutical supply, research platform construction, and clinical trial promotion [2] - Moving forward, Yuanzi Gaoke will continue to focus on the field of nuclear medicine, increase investment in radiopharmaceutical research and technological innovation, and deepen cooperation with clinical institutions to enhance precision medical development [2]

Core Insights - China Tongfu (01763) announced that the project "Establishment of a Multimodal Nuclear Medicine Molecular Imaging System for Pediatric Neuroblastoma," participated by Atomic High-Tech Co., Ltd., won the first prize at this year's Beijing Medical Science and Technology Awards [1] Group 1: Project Overview - Neuroblastoma is the most common extracranial solid tumor in children, accounting for approximately 8%-10% of pediatric malignant tumors and leading to about 10%-15% of childhood cancer-related deaths [1] - The project focuses on addressing the challenges posed by neuroblastoma, which has a poor prognosis with a 5-year survival rate of less than 50% for high-risk patients [1] - The project aims to establish a complete independent innovation chain for neuroblastoma diagnosis and treatment, utilizing multimodal nuclear medicine molecular imaging technology [1] Group 2: Contributions of Atomic High-Tech - Atomic High-Tech has played a key role in the development of radiopharmaceuticals for neuroblastoma, including the successful registration of sodium fluoride injection, filling a gap in domestic bone imaging radiopharmaceuticals [2] - The company has established a long-term strategic partnership with Friendship Hospital, focusing on collaborative innovation in radiopharmaceutical supply, research platform construction, and clinical trial advancement [2] - Future efforts will include increased investment in radiopharmaceutical research and technology innovation, aiming to enhance precision medicine and safeguard public health [2]